Abstract
PPARγ regulates the expression of numerous genes. In addition to their anti-diabetic activity, PPARγ agonists have been reported to have beneficial effects for cancer, inflammation including inflammatory bowel disease, atherosclerosis and brain inflammation, as well as bone turnover. To investigate a potential new class of ligands for PPARγ, we designed with reference to the crystal structure of the ligand-binding domain of PPARγ oxidized docosahexaenoic acid (DHA) derivatives, which have a hydrophilic substituent at the C(4)-position and are putative metabolites of DHA. We synthesized 14 compounds and evaluated their activities in vitro. We found that these DHA derivatives show PPARγ transactivation higher than, or comparable to, that of pioglitazone, which is a thiazolidinedione derivative used as an antidiabetic agent. Furthermore, one of them showed anti-diabetic activity in animal models. In this paper, we review the potential of PPARγ as a drug target and oxidized DHA as a new class of ligand for PPARγ.
Similar content being viewed by others
References
Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF (2005) Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25:1647–1653
Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptorγ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854–860
Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL (2006) PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290:H390–H397
Berk BC, Haendeler J, Sottile J (2000) Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest 105:1525–1526
Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L (2005) Nuclear receptor peroxisome proliferator-activated receptorγ is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem 92:895–903
Bishop-Bailey D, Hla T (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ2, 14-prostaglandin J2. J Biol Chem 274:17042–17048
Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ (2005) Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25:1903–1909
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558–567
Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K (2001) Structure of the PPARα and -γ ligand binding domain in complex with AZ242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699–706
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C (2003) Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptorγ (PPARγ), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140:366–376
Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptorγ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951–3956
Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT (2005) The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 3:11
Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, Spiegelman BM (2005) Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev 19:362–375
Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341–1349
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779–18789
Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE (2000) Asymmetry in the PPARγ/RXRγ crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545–555
Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2007) Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 21:231–244
Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM (2007) Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11:395–406
Giulian D (1999) Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 65:13–18
Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:214–228
Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173–182
Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K (2006) Synthesis of docosahexaenoic acid derivatives designed as novel PPARγ agonists and antidiabetic agents. Bioorg Med Chem 14:98–108
Kintscher U, Lyon CJ, Law RE (2004) Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9:359–369
Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819
Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS (2002) A phase II study of troglitazone, an activator of the PPARg receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8:395–399
Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer’s disease. Neurobiol Aging 22:937–944
Lyseng-Williamson KA (2007) Sitagliptin: a guide to its use in type 2 diabetes. Drugs 67:587–597
Mudaliar S, Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239–257
Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR (2000) Peroxisome proliferator-activated receptorγ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309–2317
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptorγ. Nature 395:137–143
Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A (2002) PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923–932
Patel CB, De Lemos JA, Wyne KL, McGuire DK (2006) Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism. Diab Vasc Dis Res 3:65–71
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptorγ. J Exp Med 201:1205–1215
Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406
Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon De La Lastra C (2005) Rosiglitazone, an agonist of peroxisome proliferator-activated receptorγ, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69:1733–1744
Sassa Y, Hata Y, Aiello LP, Taniguchi Y, Kohno K, Ishibashi T (2004) Bifunctional properties of peroxisome proliferator-activated receptorγ1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes 53:1222–1229
Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354
Staels B (2005) PPARγ and atherosclerosis. Curr Med Res Opin 21(Suppl 1):S13–S20
Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M (2005) Linkage to peroxisome proliferator-activated receptorγ in SAMP1/YitFc mice and in human Crohn’s disease. Gastroenterology 128:351–360
Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, Tsugane S, Nishiwaki Y, Miyaoka H, Uchitomi Y (2004) Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 90:787–793
Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptorγ and the retinoid X receptor. Proc Natl Acad Sci U S A 94:237–241
Vanden Heuvel JP (2007) The PPAR resource page. Biochim Biophys Acta 1771:1108–1112
Wang T, Xu J, Yu X, Yang R, Han ZC (2006) Peroxisome proliferator-activated receptorγ in malignant diseases. Crit Rev Oncol Hematol 58:1–14
Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptorγ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116–9121
Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98:13919–13924
Yamamoto K, Sun WY, Ohta M, Hamada K, DeLuca HF, Yamada S (1996) Conformationally restricted analogs of 1α,25-dihydroxyvitamin D3 and Its 20-epimer: compounds for study of the three-dimensional structure of vitamin d responsible for binding to the receptor. J Med Chem 39:2727–2737
Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S (2005) Identification of putative metabolites of docosahexaenoic acid as potent PPARγ agonists and antidiabetic agents. Bioorg Med Chem Lett 15:517–522
Yli-Jama P, Meyer HE, Ringstad J, Pedersen JI (2002) Serum free fatty acid pattern and risk of myocardial infarction: a case-control study. J Intern Med 251:19–28
Acknowledgment
We thank Dr. John Schwabe of Department of Biochemistry, University of Leicester (Leicester, UK) for helpful comments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Itoh, T., Yamamoto, K. Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand. Naunyn-Schmied Arch Pharmacol 377, 541–547 (2008). https://doi.org/10.1007/s00210-007-0251-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-007-0251-x